证券日报网讯 1月14日，欧普康视在互动平台回答投资者提问时表示，截至2026年1月9日，公司股东总 人数为64207户。 （文章来源：证券日报） ...

Group 1 - The core point of the article is that Opcon Vision has reported an expected total number of shareholders to reach 61,940 by December 31, 2025 [2]

Core Viewpoint - The company Ophthalmic Vision Technology Co., Ltd. (欧普康视) has shown a mixed financial performance with slight revenue growth but a significant decline in net profit, indicating potential challenges ahead in maintaining profitability while managing investor sentiment and market position [2][3]. Financing and Trading Activity - On January 6, the stock price of Ophthalmic Vision increased by 1.69%, with a trading volume of 463 million yuan. The financing buy-in amount for the day was 51.27 million yuan, while the financing repayment was 46.70 million yuan, resulting in a net financing buy of 457.09 thousand yuan. The total financing and securities balance reached 613 million yuan [1]. - The current financing balance of 609 million yuan accounts for 4.20% of the circulating market value, which is above the 60th percentile level over the past year, indicating a high level of financing activity [1]. - In terms of securities lending, 900 shares were repaid, and 195,900 shares were sold short, amounting to 3.18 million yuan at the closing price. The remaining short selling volume was 269,000 shares, with a balance of 4.36 million yuan, also above the 50th percentile level over the past year [1]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 1.433 billion yuan, reflecting a year-on-year growth of 0.13%. However, the net profit attributable to shareholders decreased by 15.41% to 442 million yuan [2]. - Since its A-share listing, the company has distributed a total of 949 million yuan in dividends, with 576 million yuan distributed over the past three years [3]. Shareholder Structure - As of December 19, the number of shareholders for Ophthalmic Vision was 61,900, a slight decrease of 0.02% from the previous period. The average circulating shares per person increased by 0.02% to 10,797 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by major ETFs, such as Huabao Zhongzheng Medical ETF and E Fund Growth ETF, while a new shareholder, Penghua Medical Technology Stock A, entered the top ten with 3.90 million shares [3].

Group 1 - Lichong Group expects a net profit of 830 million to 870 million yuan for 2025, representing a year-on-year growth of 17.38% to 23.04% [1] - Shandong Zhanggu anticipates a net profit of 72 million to 80 million yuan for 2025, with a year-on-year increase of 0.65% to 11.83% [2] - Yinglian Co. forecasts a net profit of 32 million to 42 million yuan for 2025, marking a turnaround from a loss of 39.67 million yuan in the previous year [3] Group 2 - Hangya Technology announces plans for shareholders to reduce their holdings by up to 2.76% of the company's shares [4] - Guizhou Tire plans to invest in a project in Morocco to produce 6 million semi-steel radial tires annually, with a total investment of 299 million USD [5] - Laisentongling's shareholder plans to reduce their stake by no more than 1% [6] Group 3 - ST Yifei's shareholder intends to reduce their holdings by up to 1.53% [7] - Hengyi Petrochemical has fully launched the second phase of its Brunei refining project, aiming for a production capacity of 12 million tons per year [8] - Zai Sheng Technology's controlling shareholder has terminated an agreement to transfer part of the company's shares [9] Group 4 - Sry New Materials proposes a cash dividend of 0.4 yuan per 10 shares for the first three quarters of 2025 [10] - Quanyin High-Tech announces that the offer period for China Seed Group's acquisition has expired, leading to a temporary suspension of its stock [11] - Zhonggang Luonai's shareholder plans to reduce their stake by up to 1% [12] Group 5 - Nanmo Bio expects to receive a government subsidy of 5.8 million yuan for its subsidiary [13] - Beite Technology has received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [14] - Qianyuan Pharmaceutical's subsidiary has obtained drug registration certificates for a new medication [15] Group 6 - Boto Integrated plans to reduce its holdings by no more than 1% [16] - Wanze Co. intends to reduce its stake by up to 1.66% [17] - Tianci Materials will halt production for maintenance on its lithium hexafluorophosphate production line starting March 1, 2026 [18] Group 7 - Haopeng Technology plans to raise up to 800 million yuan through a private placement [20] - Yisheng Co. reports a 43.32% year-on-year increase in sales revenue for its white feather broiler chicks in December 2025 [21] - Jinyu Medical proposes a cash dividend of 8.8 yuan per 10 shares for the first three quarters of 2025 [22] Group 8 - Caesar Travel's subsidiary has won a management service project for the Qingdao International Cruise Port [23] - Kelun Pharmaceutical plans to repurchase shares worth 50 million to 100 million yuan [24] - Jiangling Motors reports a 10.56% year-on-year increase in cumulative sales for 2025 [25] Group 9 - Yilian Technology plans to issue convertible bonds to raise up to 1.2 billion yuan [26] - Shaanxi Guotou A intends to participate in a capital increase for Chang'an Bank, with an amount not exceeding 800 million yuan [27] - Oupokang Vision has obtained a production license for eye drops [28] Group 10 - Shanghai Electric plans to provide management services for overseas assets of China Electric International [30] - Yingfang Micro is planning a major asset restructuring, leading to a temporary suspension of its stock [31] - Victory Energy's stock will resume trading after completing a verification process [32] Group 11 - China Merchants Industry has signed a shipbuilding agreement with Dalian Shipbuilding [33] - Kunyu Group has appointed a new chairman following a board meeting [34] - Microchip Bio's clinical trial application for a new diabetes treatment has been accepted [35] Group 12 - Hanshuo Technology has signed a sales intention agreement for smart shopping carts with Woolworths in Australia [36] - Zhongmin Energy's three photovoltaic power station projects have been included in the Fujian Province development list [37] - Penghui Energy plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [38] Group 13 - Victory Energy reports that the acquirer has deposited a guarantee for the acquisition [39] - Fangsheng Pharmaceutical proposes a special dividend of 0.15 yuan per share for 2025 [40] - Nanning Department Store has received approximately 14.28 million yuan in government subsidies since January 2025 [41] Group 14 - Jushen Co. has signed a bauxite transfer agreement with a company in Guinea [42] - ST Huluwawa has received a drug registration certificate for a new inhalation solution [43] - Zhongzhi Co. will become the controlling shareholder following a share transfer agreement [44] Group 15 - Chuangli Group has signed a strategic cooperation framework agreement with Chuanjiu Construction [45]

Core Viewpoint - The company, Opcon Vision (300595), has recently received a Drug Production License for eye drops from the Anhui Provincial Drug Administration, marking its first acquisition of such a license [1] Group 1: License Acquisition - The Drug Production License is a significant regulatory milestone for the company, allowing it to proceed with further necessary regulatory steps for commercialization [1] - The company must still complete product registration applications, on-site inspections, and compliance checks with Good Manufacturing Practices (GMP) before obtaining the Drug Registration Certificate [1] Group 2: Impact on Business - The acquisition of the Drug Production License is not expected to have a significant short-term impact on the company's operating performance [1]

Core Viewpoint - The company has recently obtained a "Drug Manufacturing License" from the Anhui Provincial Drug Administration, marking its first acquisition of such a license, which is expected to positively influence the company's long-term development [1] Group 1 - The acquisition of the "Drug Manufacturing License" will help optimize the company's product structure [1] - The company still needs to complete regulatory procedures, including product registration application, on-site verification, and compliance checks with GMP, before obtaining the "Drug Registration Certificate" for commercial production and sales [1] - The short-term impact of the "Drug Manufacturing License" on the company's operating performance is expected to be minimal [1]

证券代码：300595 证券简称：欧普康视 公告编号：2026-002 1、企业名称：欧普康视科技股份有限公司 2、统一社会信用代码：91340100723323559X 3、住址（经营场所）：合肥市高新区望江西路 4899 号 欧普康视科技股份有限公司 关于取得《药品生产许可证》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 欧普康视科技股份有限公司（以下简称"公司"）于近日收到安徽省药品监 督管理局颁发的《药品生产许可证》。现将具体情况公告如下： 一、《药品生产许可证》的基本信息 二、对公司的影响及风险提示 4、许可证编号：皖 20250658 5、分类码：Ah 6、法定代表人：陶悦群 7、企业负责人：王殿阔 8、质量负责人：郝展飞 9、生产负责人：陈平 10、质量受权人：郝展飞 11、生产地址和生产范围：合肥市高新区望江西路 4899 号：滴眼剂（注： 未进行药品 GMP 符合性检查，仅限注册申报使用） 12、有效期至：2030 年 12 月 25 日 13、签证机关：安徽省药品监督管理局 本次系公司首次取得《药品生产许可证》，有利于优化公司产品 ...

证券代码：300595 证券简称：欧普康视 公告编号：2026-001 欧普康视科技股份有限公司 关于持股5%以上股东部分股份补充质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 欧普康视科技股份有限公司（以下简称"公司"）于近日收到公司持股 5% 以上股东南京欧陶信息科技有限公司（以下简称"南京欧陶"）的通知，获悉其 将持有公司部分股份补充质押给招商证券股份有限公司。现将具体情况公告如下： 一、股东股份质押的基本情况 注：本公告中所涉数据的尾数差异或不符系四舍五入所致。 2、股份累计被质押的情况 截至本公告披露日，南京欧陶所持质押股份累计情况如下： | | | | 名称 | | 股东 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 量（股） | | 持股数 | | | | | | | （%） 量（股） | | 比例 质押股份数 | 持股 本次质押前 | | | | | | | 量（股） | | 质押股份数 | 本次质押后 | | | | | | （%） ...

Core Viewpoint - The company emphasizes the importance of communication with all shareholders and ensures transparency of information through various channels [1] Group 1: Shareholder Communication - The company has been actively engaging with shareholders through multiple platforms to maintain transparency [1] - The company has conducted online and offline product coupon return activities for shareholders for two consecutive years [1] - The company plans to conduct another shareholder return activity, with specific plans to be announced later [1]

Group 1 - The Anhui Provincial Health Commission and other authorities have released the first batch of "new quality drug and medical device" product catalog to accelerate the promotion and application of innovative medical products, fostering new productive forces in the biopharmaceutical industry [1] - A total of 60 "new quality drug and medical device" products were announced, with 45 products from Hefei, accounting for 75% of the total in the province, highlighting Hefei's strong innovation capabilities and industrial clustering effect [1] - In the biopharmaceutical sector, all three selected biopharmaceuticals in the province are from Hefei, including innovative drugs for tuberculosis/influenza prevention by Zhifei Longcom and anti-tumor drugs by Anke Bio [1] Group 2 - Hefei's Industrial and Information Technology Bureau is actively promoting the innovative development of the biopharmaceutical industry, focusing on building a collaborative industrial ecosystem involving government, industry, academia, research, application, and finance [2] - The city is nurturing local leading enterprises such as Anke Bio, Opcon Vision, and Meiya Optoelectronics while successfully attracting innovative companies like Ruisi Digital Technology through high-level platforms [2] - Collaboration with institutions like the University of Science and Technology of China and Anhui University of Traditional Chinese Medicine has led to the incubation of technology-based SMEs, creating a favorable development pattern for large, medium, and small enterprises [2]